Key result
Female gender was not associated with increased accumulated target-lesion revascularization rates compared to males (2.7% vs. 2.0%; P=0.101) following PCI with polymer-free sirolimus-eluting stents.
Why the study?
Gender-specific outcomes after percutaneous coronary interventions had been studied across varying endpoints and ethnic cohorts, but gender differences after treatment with polymer-free sirolimus-coated stents remained to be determined.
Does female gender affect clinical outcomes in patients undergoing percutaneous coronary interventions with polymer-free sirolimus-eluting stents?
Cohort
Yes
Does female gender affect clinical outcomes in patients undergoing percutaneous coronary interventions with polymer-free sirolimus-eluting stents?
Absolute Event Rate: 2.7% vs 2%
p-value: p=0.101
In patients undergoing PCI with polymer-free sirolimus-eluting stents, female gender is not an independent predictor of increased MACE after adjusting for age and comorbidities.
No sex difference in TLR after polymer-free sirolimus-eluting stent PCI; leaves open randomized confirmation.
BACKGROUND: Gender-specific outcomes after percutaneous coronary interventions were studied by a number of research groups with different endpoints and cohorts of different ethnic extractions. The purpose of this report is to use propensity score matching to determine gender-specific differences in clinical outcomes after percutaneous coronary interventions with polymer-free sirolimus-coated stents. MATERIALS AND METHODS: The basis for this post hoc analysis was two large all-comers studies with prospectively enrolled patients from Europe and Asia. Data were pooled and analyzed in terms of clinical outcomes to assess the impact of gender in patients with stable coronary artery disease and acute coronary syndrome. The primary endpoint was the accumulated target-lesion revascularization rate whereas secondary endpoints consisted of the event rates for major adverse cardiac events (MACE), myocardial infarction, bleeding events and death from all causes. The purpose of these post hoc analyses was to detect potential differences in clinical outcomes between females and males in unselected and propensity-score-matched cohorts. RESULTS: Overall, in the unmatched cohorts, accumulated target-lesion revascularization rates did not differ between both genders (2.7% vs. 2.0%; P = 0.101), however, accumulated MACE rates were higher in females than in males (5.2% vs. 3.9%; P = 0.020). After propensity-score-matching, primarily adjusting for age, hypertension and diabetes, our data revealed similar accumulated MACE in women and men (5.5% vs. 5.2%; P = 0.749). In the unmatched STEMI subgroup, all-cause mortality was significantly higher in females driven by older age ( P < 0.001). CONCLUSION: In the propensity-score-matched real-world cohorts, female gender was not a predictor for increased rates of accumulated MACE. In the unmatched STEMI subgroup, all-cause mortality was significantly higher in females due to older age. Age seems to be the determining factor for increased clinical event rates and not gender.
No takes yet. Share an insight, caveat, or question.
Krackhardt et al. (2023) conducted a cohort in Stable coronary artery disease and acute coronary syndrome. Female gender vs. Male gender was evaluated on Accumulated target-lesion revascularization rate (p=0.101). Female gender was not associated with increased accumulated target-lesion revascularization rates compared to males (2.7% vs. 2.0%; P=0.101) following PCI with polymer-free sirolimus-eluting stents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: